The first aim of this review is to analyze the pre-clinical evidence regarding a possible connection between Aβ reduction and Tau reduction and the other way around, followed by an analysis of AD monoclonal antibody clinical trials results in which one hallmark influences the other. Here, MAPT is linked to Alzheimer disease.